Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Børge Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn, JUPITER Study Group, Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P KasteleinWolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn, JUPITER Study Group

    108 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)'. Together they form a unique fingerprint.

    Medicine & Life Sciences